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Prevalencea urine microalbumin-to-creatinine ratio 30 mg/g, and/or a protein 1 þ on urine dipstick
examination, and/or an estimated glomerular filtration rate<60 mL/min/1.73 m2 for 3 months.
The prevalence rate and the analyzed associated factors of CKD were determined.
Results: Among 1639 HIV-infected patients, only 512 had adequate data to be enrolled in the
study. Thirty-six (7.03%) of these patients had CKD, and 476 did not. In a univariate analysis,
CKD was associated with an older age, a higher peak HIV RNA load, diabetes mellitus (DM), hy-
pertension, exposure to antiretroviral therapy, and cholesterol levels 240 mg/dL. Multivar-
iate analysis revealed that DM, hypertension, and cholesterol 240 mg/dL were statistically
significant factors.
Conclusion: In Taiwan, the prevalence of CKD in HIV-infected patients was low (7.03%). The
classical risk factors for CKD, such as DM, hypertension, and hypercholesterolemia, were
demonstrated to be associated with CKD in Taiwanese HIV-infected patients.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Following the introduction of the wide use of highly active
antiretroviral therapies (ARTs), the median survival of
human immunodeficiency virus (HIV)-infected patients has
increased remarkably, and the outcome of renal compli-
cations, such as the risk of end-stage renal disease and 1-
year survival in patients with dialysis, also improved.1e3
Despite this improvement, chronic kidney disease (CKD) is
an important issue in managing HIV-infected patients due to
the associated higher mortality rate.4 The literature states
that CKD in HIV-infected patients results from various fac-
tors, including HIV-associated nephropathy, severe HIV
infection, black ethnicity, diabetes mellitus (DM), hyper-
tension, and aging.3,5 Although highly active ART can
reduce HIV-associated nephropathy, nearly all antiretrovi-
ral drugs have been reported to cause renal dysfunction.3
The most notable antiretroviral drugs to be associated
with renal disease have been indinavir and tenofovir.3
Regular urinalyses are recommended in the USA and
Europe.5,6 The prevalence of CKD in HIV-infected patients
ranges from 3% to 38% in different races and countries.7e11
Among the different races, African Americans have been
determined to be more prone to develop CKD and end-stage
renal disease.12,13 The prevalence of CKD in the general
Taiwanese population was found to be 11.93%, with CKD
cases having a higher mortality rate and cardiovascular
disease risk.14 However, the data for CKD in Taiwanese HIV-
infected patients are lacking. We conducted a study to
evaluate the prevalence and associated factors of CKD in
HIV-infected patients in Taiwan.Materials and methods
Study population
This was a retrospective cross-sectional study. The data
were collected from HIV-infected patients who were fol-
lowed in a medical center and a regional teaching hospital
in southern Taiwan. In the medical center, the study period
was from January 2008 to December 2012; in the regional
teaching hospital, the study period was from January 2010to December 2012. The present study was approved by the
Institutional Review Board of Kaohsiung Medical University
Hospital; registration number, KMUHIRB-20120020.
Definitions
The CKD diagnostic criteria were defined as a urine
microalbumin-to-creatinine ratio (ACR) 30 mg/g, and/or a
protein 1 þ on urine dipstick examination, and/or an
estimated glomerular filtration rate (eGFR) <60 mL/min/
1.73 m2 persisting for at least 3 months.15 The estimated
glomerular filtration rate was calculated using the simpli-
fied modification of diet in renal disease formula.16 The
CKD cases were classified into five stages according to the
eGFR level. The eGFRs for Stage 1 to Stage 5 were defined
as follows: 90 mL/min/1.73 m2; 60e89 mL/min/1.73 m2;
30e59 mL/min/1.73 m2; 15e29 mL/min/1.73 m2; and
<15 mL/min/1.73 m2 or dialysis.15 The patients who did not
meet any given diagnostic criterion were defined as non-
CKD. The method to determine urine microalbumin was
tested by conjugation of specific antigen and urine micro-
albumin, and detected by the Synchron System (Beckman
Coulter, Pasadena, CA, USA).
Each patient’s characteristics were also recorded,
including the following metrics: age; sex; body weight;
serum creatinine; DM status; hypertension; hepatitis B and
C infection status; cholesterol level; triglycerides; high-
and low-density lipoprotein levels; HbA1c level; the dura-
tion of HIV infection; the peak HIV RNA load and the CD4
cell count nadir following the diagnosis of HIV infection;
and the exposure to ARTs. DM was defined as a diagnosis of
DM previously, or use of oral antidiabetic agents or insulin.
Hypertension was defined as a systolic blood pressure
>140 mmHg and/or a diastolic blood pressure >90 mmHg,
or use of antihypertensive agents. Hepatitis B infection was
defined as being positive for the surface antigen, and
hepatitis C (HCV) infection was defined as being anti-HCV
antibody-positive. The lipid profiles were recorded as
cholesterol 240 mg/dL, high-density lipoprotein <40 mg/
dL,17 triglycerides >150 mg/dL, and low-density lipoprotein
>130 mg/dL.
Exposure to ART was defined as exposure to ART for at
least 3 months. The exposure to each antiretroviral drug
258 M.-H. Hsieh et al.was required to be at least 3 months for it to be considered
in the present analysis. The patients who did not have a
medical record of receiving ART from the beginning of such
treatment were not included in the analysis of the effects
of exposure to the given antiretroviral drug. The patients
without a medical record for the initial CD4 cell count or
HIV RNA load were not included for the analysis of these
variables.
Statistical analysis
SPSS version 19 software (SPSS, Chicago, IL, USA) was used
for the statistical analysis. The characteristics of patients
with and without CKD were compared. The data are pre-
sented as the mean  standard deviation. For the univari-
ate analysis, the independent samples t tests were used for
the continuous variables, and the Chi-square test or
Fisher’s test were used for the categorical variables.
Fisher’s test was used if the magnitude of the categorical
variable was <5. Logistic regression analysis was applied for
the multi-variable analyses. The variables with p <0.05 in
the univariate analyses were included in the logistic
regression. The CD4 cell count nadir was also included in
the logistic regression given that this metric is an important
factor in HIV-infected patients.
Results
The present study screened 1639 patients who were fol-
lowed during the study period. Of these, 487 patients had
never received a urine dipstick examination or an ACR
measurement. The CKD status of 624 patients could not be
determined due to inadequate data (Fig. 1). The patients
without adequate data for the determination of CKD had
only urine dipstick or ACR data or proteinuria for
<3 months. Of the remaining 512 patients, 36 had CKD and
476 did not. Among the patients with CKD, 11.11% (4/36)
matched the diagnostic criterion of eGFR <60 mL/min/
1.73 m2, 41.67% (15/36) matched the diagnostic criterion of
ACR >30 mg/g, and 52.78% (19/36) matched the diagnostic
criterion of traceable proteinuria by urine dipstick exami-
nation. The prevalence rate of CKD diagnosed by K/DOQIFigure 1. Flow chart of study design. a Patients without
adequate data included patients with only normal urine
dipstick examination or normal ACR which cannot be deter-
mined if non-CKD, and patients with proteinuria without ful-
filled with criteria of lasting for 3 months. ACR Z urine
microalbumin-to-creatinine ration; CKD Z chronic kidney
disease.diagnostic criteria was 7.03%. The prevalence rates of CKD
diagnosed by diagnostic criteria of eGFR <60 mL/min/
1.73 m2, eGFR <60 mL/min/1.73 m2 combined with ACR
>30 mg/g, and eGFR <60 mL/min/1.73 m2 combined with
traceable proteinuria detected by dipstick were 0.78%,
3.52%, and 4.49%, respectively. The mean age of the
included 512 patients was 36.87  10.24 years, and 471
were male. The prevalence rates of DM and hypertension
were 5.4% (26/482) and 7.56% (31/410), respectively. The
mean creatinine level was 0.86  0.47 mg/dL, and the
mean eGFR was 113.36  24.51 mL/min/1.73 m2. The mean
peak plasma HIV RNA load was 4.93  0.88 log10/mL
(n Z 240), and the mean CD4 cell count nadir was
206.15  152.92 cells/mL (n Z 241). Among the examined
population, 55.69% (279/501) received ART. The mean
duration of ART was 57.56  48.10 months (n Z 234).
The prevalence rates of CKD in the different age groups
were as Fig. 2: 0% (0/2) in those who were aged 15e19 years,
3.7% (2/54) in those who were aged 20e24 years, 4.23% (3/
71) in those who were aged 25e29 years, 4.81% (5/104) in
those who were aged 30e34 years, 3.96% (4/101) in those
who were aged 35e39 years, 9.21% (7/76) in those
who were aged 40d44 years, 16% (8/50) in those who were
aged 45e49 years, 3.85% (1/26) in those who were
aged 50e54 years, 8.33% (1/12) in those who were aged
55e59 years, 25% (2/8) in those who were aged 60e64 years,
and 37.5% (3/8) in those who were aged 65 years. The
majority of our cases were younger than 50 years. In the
patients who were younger than 50 years, the prevalence of
CKD increased remarkably in the group that was age
40e49 years. The estimated crude incidence of CKD is 9.77/
1000 personeyears in those patients who were newly diag-
nosed with HIV infection and received follow-up during the
study period.
The characteristics of the HIV-infected patients with and
without CKD are compared in Table 1. The analyses indi-
cated that CKD was associated with an older age, DM, hy-
pertension, cholesterol 240 mg/dL, higher peak plasma
HIV RNA load, ART exposure, and non-HCV coinfection. No
specific category of ART was associated with CKD. In the
multivariate analysis, age, peak plasma HIV RNA load, and
CD4 cell nadir were analyzed as continuous variables and
the others were as categorical variables. As a result, CKD
was only related to DM [odds ratio (OR), 9.822; 95% confi-
dence interval (CI), 1.862e51.803; p Z 0.007], hyperten-
sion (OR 23.060; 95% CI, 4.670e113.874, p <0.001), and
cholesterol 240 mg/dL (OR, 5.523; 95% CI, 1.236e24.686;
p Z 0.025; Table 2). Based on the multivariate analysis,
there were no statistically significant results with respect
to ART exposure, even when using 6-month, 12-month, or
24-month treatment duration as the definition of ART
exposure.
In 36 patients with CKD, 17 (47%) were CKD Stage 1, 13
(36%) were Stage 2, three (8%) were Stage 3, one (3%) was
Stage 4, and two (6%) were Stage 5. In 21 CKD patients with
data of ACR, six with ACR >300 mg/g, 12 with ACR
30e300 mg/g, and the remaining three had ACR <3 mg/g.
Fourteen cases had CKD at the time of HIV diagnosis. For
the 12 patients who did not have CKD at the time of HIV
diagnosis, 11 received ART when CKD was confirmed. The
mean time of CKD development following ART in these
patients was 80.0  55.2 months.
Figure 2. Prevalence of chronic kidney disease (CKD) in each age group.
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In the present study, we evaluated the prevalence of CKD
in HIV-infected patients in two teaching hospitals in
southern Taiwan. The prevalence of CKD in this population
was 7.03%, a rate similar to the general Taiwanese popu-
lation of the same age,18 but much lower than other Asian
HIV-infected populations (15.4% in Japan and 16.8% in Hong
Kong).9,10 Yanagisawa et al9 analyzed 732 HIV-infected
Japanese with a mean age of 46.7  12 years, and the
prevalences of DM, hypertension, and CKD were 7.9%,
30.3% and 15.4%, respectively. Of the patients in this pre-
vious cohort, 90.7% received ART; specifically, 50.5% had
received tenofovir, and 7.9% had received indinavir. In
another study conducted in Hong Kong by Cheung et al,10
the data from 322 HIV-infected Chinese patients (mean
age: 45.2  11.7 years) were analyzed. The prevalences of
DM, hypertension, and CKD were 7.4%, 10.6%, and 16.8%,
respectively. Of this group, 93.5% had received ART; spe-
cifically, 5.3% of the patients had received tenofovir, and
33.2% had received indinavir. Compared to the previous
studies, the percentage of ART exposure was lower in the
present study population and had lower rates of tenofovir
or indinavir exposure. Moreover, the mean age of the
present study population was 36.87  10.24 years, which
was approximately 10 years younger than the populations
from Hong Kong and Japan. The prevalence of CKD in the
general population has been reported to increase with
age.14,18 The younger age of the participants in the present
study may in part explain the low prevalence of CKD
observed. The majority of the present study population
was younger than 50 years. In the patients who were
younger than 50 years, the CKD prevalence increased
remarkably after age 40 years. This finding was consistentwith the CKD prevalence in the general Taiwanese
population.14
According to current recommendations, urinalysis was
suggested when HIV-infected patients enter into care and
during their regular annual monitoring.19 However,
approximately 29.7% of patients never received a urinalysis
in our hospitals. Early stage CKD screening is of poor qual-
ity, and the majority of the patients with CKD in the present
study were Stage 1 or Stage 2. Efforts to encourage physi-
cians to screen for proteinuria in HIV-infected patients are
required. This testing can identify patients with early stage
CKD and rapidly avoid the use of nephrotoxic agents.
In previous studies, the risk factors that have been
associated with CKD in HIV-infected patients included lower
CD4 cell count nadir, the duration of ART, exposure to in-
dinavir or tenofovir, the duration of tenofovir use, older
age, hypertension, and DM.3,7,8,10,20 In the present study,
the peak HIV RNA load and ART exposure were associated
with CKD in the univariate but not in the multivariate
analysis.
Previous studies have reported that tenofovir, indinavir,
or tenofovir in combination with protease inhibitors were
related to CKD.20e22 Drugs have been shown to be highly
associated with tubulointerstitial nephropathy in HIV-
infected patients in a study by Zaidan et al,23 which
including renal biopsy result, and antiretroviral drugs were
strongly associated with tubulopathy, especially tenofovir.
However, in the present study, the individual drugs were
not statistically significantly associated with CKD, not even
tenofovir or indinavir. This result is likely to be primarily
due to the low rate of tenofovir and indinavir exposure in
the examined population.
Nevertheless, DM, hypertension, and cholesterol
240 mg/dL were significantly associated with CKD in both
Table 1 The characteristics of HIV-infected patients with and without chronic kidney disease
CKD, n Z 36 (%) Non-CKD, n Z 476 (%) p
Age (y) 43.22  12.78 36.38  9.87 <0.001
Male 34 437 0.758
Creatinine (mg/dL) 1.40  1.61 0.82  0.14 0.037
eGFR (mL/min/1.73 m2) 91.62  42.45 115.01  21.80 0.002
ACR (mg/g) 656.43  1475.80 (n Z 21) 6.96  9.42 0.057
Weight (kg) 69.59  22.71 66.32  11.36 (n Z 356) 0.399
Duration of HIV diagnosed (mo) 59.69  41.66 (n Z 26) 46.48  43.42 (n Z 216) 0.142
Peak plasma HIV RNA load (log10/mL) 5.3  0.75 (n Z 26) 4.89  0.89 (n Z 214) 0.024
CD4 cell count nadir (cells/mL) 176.29  147.65 (n Z 26) 209.76  153.49 (n Z 215) 0.293
Underlying disease, n (%)
DM 12/36 (33.33) 14/446 (3.14) <0.001
Hypertension 13/35 (37.14) 18/375 (4.8) <0.001
HBV 6/34 (17.65) 76/444 (17.12) 0.973
HCV 3/36 (8.33) 168/452 (37.17) <0.001
ART exposure 31/36 (86.11) 248/465 (53.33) <0.001
IDV 2/30 (6.67) 7/204 (3.43) 0.324
TDF 2/30 (6.67) 7/204 (3.43) 0.324
NNRTI 25/30 (83.33) 145/204 (71.08) 0.160
PI 18/30 (60) 100/204 (49.02) 0.261
rPI 9/30 (30) 78/204 (38.24) 0.384
II 3/30 (10) 6/204 (2.94) 0.094
Duration of ART use (mo) 78.4  62.62 (n Z 30) 54.5  44.96 (n Z 204) 0.052
Cholesterol 240 mg/dL, n (%) 6/32 (18.75) 18/373 (4.83) 0.001
TG >150 mg/dL 15/31 (48.39) 135/374 (36.10) 0.173
HDL <40 mg/dL 12/30 (40) 166/310 (53.55) 0.156
LDL >130 mg/dL 8/30 (26.67) 47/309 (15.21) 0.104
HbA1c (%)a 7.88  1.92 (n Z 11) 7.09  1.72 (n Z 12) 0.310
a Only patients with diabetes were included in this analysis.
ACR Z urine microalbumin-to-creatinine ratio; ART Z antiretroviral therapy; CKD Z chronic kidney disease; DM Z diabetes mellitus;
eGFRZ estimated glomerular filtration rate; HbA1cZ glycated hemoglobin; HBVZ hepatitis B; HCVZ hepatitis C; HDLZ high-density
lipoprotein; HIV Z human immunodeficiency virus; IDV Z indinavir; II Z integrase inhibitor; LDL Z low-density lipoprotein;
NNRTI Z non-nucleoside reverse transcriptase inhibitor; PI Z protease inhibitor; rPI Z boosted protease inhibitor; TDF Z tenofovir;
TG Z triglycerides.
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consistent with the general population.15,17 This result may
suggest that in Asian HIV-infected patients without
indinavir or tenofovir exposure, DM, hypertension, andTable 2 Multivariate analysis for risks of chronic kidney
disease in HIV-infected patients
Variable OR 95% CI p
Age 0.975 0.916e1.038 0.433
DM 9.822 1.862e51.803 0.007
Hypertension 23.060 4.670e113.874 <0.001
Cholesterol 240 mg/dL 5.523 1.236e24.686 0.025
Peak plasma HIV RNA
load (log10/mL)
2.159 0.929e5.015 0.074
CD4 cell count nadir
(cells/mL)
1.001 0.997e1.005 0.722
ART exposure 6.44 0.529e78.346 0.144
HCV 0.148 0.007e3.052 0.216
ART Z antiretroviral therapy; CI Z confidence interval;
DM Z diabetes mellitus; HCV Z hepatitis C; HIV Z human
immunodeficiency virus; OR Z odds ratio.hypercholesterolemia are much more important associated
factors of CKD. The odds ratios of CKD in patients with DM
and hypertension were 9.82 and 23.06, respectively. How-
ever, the odds ratio of CKD in the general Taiwanese pop-
ulation with DM and hypertension were 4.707 and 3.892,
respectively.18 The relative association of DM and hyper-
tension was therefore much higher in the present study
group than for the general population. However, a larger
scale study is required to clarify whether DM or hyperten-
sion increases the risk of CKD in HIV-infected patients to a
greater extent than is observed in the general population.
In Taiwanese HIV-infected patients, the mortality rate
decreased after the introduction of highly active antire-
troviral therapy.24 With the prolonged survival, HIV-
infected patients received long-term antiretroviral ther-
apy. Wu et al25 demonstrated that hyperlipidemia was
associated with prolonged antiretroviral therapy, especially
protease inhibitor, in Taiwanese HIV-infected patients.
Furthermore, the association between hypercholesterole-
mia followed by antiretroviral therapy and decreased eGFR
were also observed in Abraham et al’s26 study. In Lo et al’s27
study, DM was associated with protease inhibitor exposure
in Taiwanese HIV-infected patients. DM is a traditional risk
factor of CKD. Despite DM having predominant association
CKD in HIV-infected patients in southern Taiwan 261with CKD in our study, protease inhibitors were not. This
may be because protease inhibitors used in Lo et al’s27
study were mostly indinavir, which has been identified as
a risk factor for DM.28,29 However, the percentage of in-
dinavir exposure in the present study was low, which may
suggest that the protease inhibitor was not an associated
factor of CKD in our study population.
A meta-analysis of studies of HIV-infected patients re-
ported that HCV coinfection is associated with an increased
risk of CKD and proteinuria.30 In patients with HIV and HCV
coinfection, the presence of HCV viremia was associated
with an increased risk of developing CKD.31 However, in the
present study, we found that HIV and HCV coinfection was
not associated with CKD.
In HIV-infected patients, HCV coinfection was more
commonly associated with intravenous drug abuse in
southern Taiwan.32 A HIV CRF07_BC outbreak has been
noted in intravenous drug abusers since 2004.33 In the
outbreak in southern Taiwan, of all of the patients with HIV
and HCV coinfection, 93.7% were intravenous drug abusers.
Moreover, the HIV RNA load was lower and the mean CD4þ
cell counts were higher in intravenous drug abusers.32
Therefore, patients with HCV and HIV coinfection in the
present study were assumed to have had a shorter duration
of HCV and HIV infection. Moreover, the majority of the HIV
and HCV coinfected patients in the present study were
intravenous abusers and did not receive regular follow-up
visits. This fact may explain why HCV infection was not
associated with CKD in the present study.
There were limitations of the present study. First, this is
a retrospective study. Many of patients were excluded from
the analysis, which may have influenced the reported
prevalence rates. Moreover, in comparing HIV-infected
patients with and without CKD, the number of patients
with CKD was limited, and many data cannot be completely
obtained, including peak HIV RNA load, CD4 cell count
nadir, complete medical history of ART, and biochemical
data. This limitation may have influenced the results of the
associated factors. Second, the present study did not
analyze the possible nephrotoxic agents that are often used
in HIV-infected patients, such as trimethoprim/sulfameth-
oxazole, acyclovir, amphotericin B, and nonsteroidal anti-
inflammatory drugs. This fact may have influenced the
analysis of the CKD associated factors. Third, this is a cross-
sectional study, and causality could not be determined.
Antiretroviral drugs, especially nucleoside reverse tran-
scriptase inhibitors, non-nucleoside reverse transcriptase
inhibitors, and protease inhibitors, are known to cause
hypercholesterolemia, which is believed to be related to
CKD.17,34 In the present study, there were 12 patients with
diabetes in the CKD group, and eight patients had DM at the
time of HIV infection diagnosis. There were 13 patients with
hypertension in the CKD group, and five had hypertension at
the time of HIV infection diagnosis. Despite these facts, the
present study cannot distinguish whether DM or hyperten-
sion is an HIV-related illness. Forth, we compared the risk,
sex, and age of our patients studied with those of patients
reported to Taiwan Centers for Disease Control. The sex
and risk of our patients studied were similar to all HIV-
infected patients in Taiwan. However, the percentage of
patients older than 40 years was higher in our study popu-
lation compared to that from Taiwan CDC (35.16% and22.78%, respectively). Therefore, our study population may
not represent the general HIV-infected patients in Taiwan.
Because our study population was older, the prevalence
rate may be overestimated for all HIV-infected patients in
Taiwan.
In conclusion, the prevalence of CKD in HIV-infected
patients in Taiwan was lower than in other Asian pop-
ulations. To avoid severe renal disease, regular urinalysis to
detect early stage CKD should be encouraged among phy-
sicians who care for HIV-infected patients. The associated
factors between CKD and HIV-infected patients in Taiwan
were as the classic risk factors for CKD for general popu-
lation, including DM, hypertension, and hypercholester-
olemia. However, further large-scale prospective studies
are required to clarify the impact of HIV status and ART
exposure on CKD in Taiwanese patients with HIV infection.Conflicts of interest
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